Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts:

Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied (500 mg to 9000 mg) were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted.

Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice- daily (BID) dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of viral rebound in any dose cohort during the 14 days of dosing. R7128 was generally safe and well tolerated. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant chan
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Sept. 9 Roche NimbleGen (SIX: RO, ROG; Pink ... Viejo) based genomic services provider Ambry Genetics has officially ... NimbleGen SeqCap EZ Exome workflow. They will provide ... with next-generation sequencing services for genetic research. Ambry Genetics ...
... Texas, Sept. 9 Luminex Corporation (Nasdaq: ... UBS Global Life Sciences Conference to be held September ... York. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... by Patrick J. Balthrop, president and chief executive officer, ...
Cached Medicine Technology:Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 2Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 3Luminex Corporation to Present at UBS Global Life Sciences Conference 2
(Date:4/18/2014)... 21, 2014) -- A group of scientists from ... the Sanders-Brown Center on Aging has found interesting ... neuropsychological function in Parkinson,s disease (PD). , ... the study, which assessed cognitive function in depressed ... dopamine replacement therapy commonly used to treat motor ...
(Date:4/18/2014)... The Gerontologist reports that among older ... decrease in anxiety about death and increases in life ... In particular, listening to gospel music is associated with ... in sense of control. , These associations are similar ... of both low- and high-socioeconomic status. , The article, ...
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... Diego, Calif. (April 18, 2014) ― A new study ... analyzing weekly patterns in health-related Google searches reveals a ... health strategies. , Investigators from San Diego ... and the Monday Campaigns, analyzed "healthy" Google searches (searches ... e.g., "healthy diet") originating in the U.S. from 2005 ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Oct. 27 Inspired by recent breakthroughs in research, today ... initiative entitled Research to Reality: Funding Progress. ... progress of crucial research, and bring promise to reality. ... battle with Rett syndrome in 2003 at age 16, will ...
... 2009 A diverse group of health care ... week that are designed to promote better medication ... The group, which includes the American College of ... Stores, the National Consumers League and the Pharmaceutical ...
... the world use medicines based on statins to lower their ... published in the prestigious journal PNAS, shows that statins may ... Statins lower cholesterol by blocking certain enzymes involved in our ... important lipids in the body, such as the lipids that ...
... developing a range of miniaturised wearable and track-side sensors, ... British athletes improve their performance on the world stage, ... will be officially launched tomorrow (28 October 2009). ... Sensing (ESPRIT) project is funded by the EPSRC and ...
... lead and some had known skin allergens , TUESDAY, Oct. ... are set to paint their faces this Halloween to look ... according to a new report released just in time for ... Safe Cosmetics, is titled: Pretty Scary: Could Halloween Face ...
... 27 Polar ( www.polarusa.com ), the leader in ... technology today introduced two new training computers designed to ... clear guidance, feedback and easy-to-use features including heart rate, which can ... person is using a heart rate monitor for the first time ...
Cached Medicine News:Health News:IRSF Receives 1 Million Dollar Matching Gift 2Health News:IRSF Receives 1 Million Dollar Matching Gift 3Health News:IRSF Receives 1 Million Dollar Matching Gift 4Health News:Experts offer policy recommendations for improving medication adherence 2Health News:Experts offer policy recommendations for improving medication adherence 3Health News:Major research collaboration will improve British athletes' performance on world stage 2Health News:Major research collaboration will improve British athletes' performance on world stage 3Health News:Toxins Make Halloween Face Paints Scary 2Health News:Toxins Make Halloween Face Paints Scary 3Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 2Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: